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Abstract
Background: In principle, the elimination of malignancies by oncolytic virotherapy could proceed by different
mechanisms - e.g. tumor cell specific oncolysis, destruction of the tumor vasculature or an anti-tumoral
immunological response. In this study, we analyzed the contribution of these factors to elucidate the responsible
mechanism for regression of human breast tumor xenografts upon colonization with an attenuated vaccinia virus
(VACV).
Methods: Breast tumor xenografts were analyzed 6 weeks post VACV infection (p.i.; regression phase) by
immunohistochemistry and mouse-specific expression arrays. Viral-mediated oncolysis was determined by tumor
growth analysis combined with microscopic studies of intratumoral virus distribution. The tumor vasculature was
morphologically characterized by diameter and density measurements and vessel functionality was analyzed by
lectin perfusion and extravasation studies. Immunological aspects of viral-mediated tumor regression were studied
in either immune-deficient mouse strains (T-, B-, NK-cell-deficient) or upon cyclophosphamide-induced
immunosuppression (MHCII+-cell depletion) in nude mice.
Results: Late stage VACV-infected breast tumors showed extensive necrosis, which was highly specific to cancer
cells. The tumor vasculature in infected tumor areas remained functional and the endothelial cells were not
infected. However, viral colonization triggers hyperpermeability and dilatation of the tumor vessels, which
resembled the activated endothelium in wounded tissue. Moreover, we demonstrated an increased expression of
genes involved in leukocyte-endothelial cell interaction in VACV-infected tumors, which orchestrate perivascular
inflammatory cell infiltration. The immunohistochemical analysis of infected tumors displayed intense infiltration of
MHCII-positive cells and colocalization of tumor vessels with MHCII+/CD31+ vascular leukocytes. However, GI-101A
tumor growth analysis upon VACV-infection in either immunosuppressed nude mice (MHCII+-cell depleted) or in
immune-deficient mouse strains (T-, B-, NK-cell-deficient) revealed that neither MHCII-positive immune cells nor T-,
B-, or NK cells contributed significantly to VACV-mediated tumor regression. In contrast, tumors of
immunosuppressed mice showed enhanced viral spreading and tumor necrosis.
Conclusions: Taken together, these results indicate that VACV-mediated oncolysis is the primary mechanism of
tumor shrinkage in the late regression phase. Neither the destruction of the tumor vasculature nor the massive
VACV-mediated intratumoral inflammation was a prerequisite for tumor regression. We propose that approaches to
enhance viral replication and spread within the tumor microenvironment should improve therapeutical outcome.
* Correspondence: aaszalay@genelux.com
† Contributed equally
1Department of Biochemistry, Biocenter, University of Wuerzburg, D-97074
Wuerzburg, Germany
Full list of author information is available at the end of the article
Weibel et al. BMC Cancer 2011, 11:68
http://www.biomedcentral.com/1471-2407/11/68
© 2011 Weibel et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.
Background
During the past several years, many reports have con-
firmed that intratumoral as well as systemic delivery of
a variety of virus strains leads to viral replication in
tumors accompanied by oncolysis of tumor cells [1-3].
Most of these replicating oncolytic viruses specifically
target solid tumors [4], which is a significant advantage
over the use of conventional chemo- and radiotherapy.
Although oncolytic viruses are successfully used as
tumor-targeting agents in animal models, the modula-
tion of the tumor microenvironment by the viruses as
well as the virus-host interaction dynamics are not well
understood and therefore, the exact underlying mechan-
ism leading to tumor elimination is less clear [5-8].
Malignant tumors are complex organ-like tissues
composed of ever-evolving neoplastic cells and non-neo-
plastic cellular components, including fibroblasts,
endothelial cells and immune cells, surrounded by an
extracellular matrix [9]. These stromal components have
an important function in maintaining and supporting
solid tumor growth and viral infection could theoretically
interfere with all of them. Moreover, viruses induce local
inflammation at sites of infection leading to local
remodeling of the infected tissue such as activation of the
vasculature and local recruitment of immune cells. Up to
date, the long-term VACV-infected tumor microenviron-
ment is not described in the literature and the mechan-
ism of VACV-mediated tumor regression is less clear.
Theoretically, three possible mechanisms may explain
virus-mediated tumor elimination - tumor cell specific
oncolysis [10], destruction of the tumor vasculature
[11,12] followed by oxygen and nutrients deprivation, an
anti-tumoral immune response [7,13], or a combination
of these mechanisms [14,15]. For optimization of oncoly-
tic virus therapy it is desired to determine which factors
contribute to most optimal virus-mediated tumor
regression.
Recently, Zhang et al. [16,17] have introduced a novel
attenuated recombinant vaccinia virus GLV-1h68 and
described its improved safety profile in comparison to
the parental wild-type LIVP strain. Furthermore, they
documented the successful application as an oncolytic
agent in therapy of human breast tumor xenografts in
nude mice.
In this study, we used the GLV-1h68 vaccinia virus
strain to investigate the factors that may contribute to
VACV-mediated tumor regression, with the final aim of
improving therapeutic outcomes. We found that GLV-
1h68 infection of GI-101A human breast tumor
xenografts in nude mice leads to specific oncolytic
destruction of the tumor tissue accompanied by tumor
shrinkage. Interestingly, endothelial cells were unin-
fected and the vasculature remained functional. How-
ever, the tumor vasculature in infected areas strongly
resembled the activated endothelium in wounded tissue,
characterized by vessel dilatation, hyperpermeability and
the increased expression of adhesion molecules. Further-
more, viral infection triggered increased expression of
genes involved in leukocytes recruitment in the late
regression phase leading to massive MHCII-positive leu-
kocytes infiltration via the activated tumor vasculature.
However, immunosuppression (MHCII+-cell depletion)
of tumor-bearing, VACV-infected animals as well as the
use of T-, B-, and NK-deficient mouse models for
tumor growth analysis revealed that none of these
immune cells are a prerequiste for VACV-mediated
GI-101A tumor regression. Our results suggested that
viral oncolysis is the critical factor for tumor elimination
in the late regression phase mediated by VACV. We
therefore propose that the most beneficial way to
improve therapeutic outcomes with the oncolytic vacci-
nia virus GLV-1h68 strain is to enhance viral replication
and spread within the tumor tissue.
Methods
Cell lines
GI-101A human ductual breast adenocarcinoma cells
were kindly provided by A. Aller (Rumbaugh-Goodwin
Institute for Cancer Research, Inc., FL, USA) and
cultured in RPMI 1640 supplemented with 5 ng/ml b-
estradiol and 5 ng/ml progesterone (Sigma Aldrich,
Taufkirchen, Germany), 1 mM sodium pyruvate, 10 mM
HEPES, 20% FBS, 100 Units/ml penicillin, and 100 μg/
ml streptomycin (PAA Laboratories, Cölbe, Germany).
African green monkey kidney fibroblasts (CV-1) were
obtained from the American Type Culture Collection
(ATCC-No. CCL-70) and cultured in DMEM supple-
mented with 10% FBS. The murine endothelial cell line
2H-11 (ATCC-No. CRL-2163) as well as mouse brain
endotheliomas bEnd.3 (kindley provided by G. J. Häm-
merling, Deutsches Krebsforschungszentrum, Heidel-
berg, Germany) were obtained in DMEM with 10% FBS.
Human umbilical vein endothelial cells (HUVEC) were
obtained from PromoCell (Heidelberg, Germany) and
cultured in M199 medium supplemented with 10% FBS,
10 ng/ml human EGF and 50 μg/ml endothelial cell
growth supplement (Sigma Aldrich). The human kidney
cell line 293FT was obtained from Invitrogen GmbH
(Karlsruhe, Germany) and cultured in DMEM supple-
mented with 10% FBS, 0.1 mM non-essential amino
acids, 6 mM L-glutamine, and 1 mM sodium pyruvat.
All cells were maintained at 37°C and 5% CO2.
Viruses and plasmids
The construction of the attenuated vaccinia virus strain
GLV-1h68 was described previously by Zhang et al. [16].
Briefly, three expression cassettes (encoding for Renilla
luciferase-GFP fusion protein, b-galactosidase and
Weibel et al. BMC Cancer 2011, 11:68
http://www.biomedcentral.com/1471-2407/11/68
Page 2 of 17
b-glucuronidase) were recombined into the F14.5L, J2R
and A56R loci, respectively, of the LIVP strain viral gen-
ome. Viruses were propagated in CV-1 cells and purified
through sucrose gradients.
The RFP-expressing GI-101A cell line was constructed
using the ViraPower™ Gateway Cloning and Lentiviral
Expression System Kit (Invitrogen GmbH, Germany) in
accordance with the manufacture’s instructions. The
mRFP-encoding plasmid pCR-TK-Sel-mRFP was provided
by Q. Zhang (Genelux Corporation, San Diego) and used
as a template for PCR amplification of the mRFP gene
using primers containing attB recombination sites for
gateway cloning (forward-attB1-mRFP: 5’-GGGGA-
CAAGTTTGTACAAAAAAGCAGGCTGCCACCATG
GCCTCCTCCGAGG-3’, reverse-attB2-mRFP: 5’-GGGGA
CCACTTTGTACAAGAAAGCTGGGTCAGAATTCGC
CCTTTCATTAGG-3’). The mRFP-containing lentiviral
vectors were generated by gateway recombination between
the pDONR-221-mRFP entry vector and the pLenti6/
V5-DEST destination vector. The mRFP-containing repli-
cation-incompetent Lentiviruses for transduction of
GI-101A cells were produced in 293FT cells using
Lipofectamine™2000 for transfection with the Vira-
Power™ Packaging Mix and the pLenti6/V5-DEST-mRFP
expression plasmid. Stable-expressing GI-101A-RFP
clones were selected using 10 μg/ml blasticidin.
Tumor inoculation and administration of the virus
All animal experiments were carried out in accordance
with protocols approved by the Regierung von Unter-
franken, Germany (permit number: 55.2-2531.01-17/08).
Six-week-old female athymic nude Foxn1nu mice were
obtained from Harlan Winkelmann GmbH (Borchen,
Germany). Six-week-old female B6.12956-Rag2tm1Fwa
N12 mice and Tac:NIHS-LystbgFoxn1nuBtkxld mice were
ordered from Taconic Inc. (Hudson, NY, USA).
GI-101A breast cancer cells (5 × 106/100 μl PBS) were
subcutaneously (s.c.) injected into the abdominal right
flank and tumor volume was calculated as (length ×
width2)/2. For all experiments, tumors were grown up
to 200-400 mm3 in size (4-6 weeks) before viral admin-
istration. A single viral dose of 1 × 106 or 5 × 106 pla-
que forming units (p.f.u.) in 100 μl PBS was injected
either intraveneously (i.v.) via the tail vein or via the
retro-orbital (r.o.) sinus vein. For r.o. injection, animals
were anesthetized using 75 mg/kg ketamine (Pfizer,
Karlsruhe, Germany) and 20 mg/kg xylazine (Bayer,
Leverkusen, Germany).
Immunohistochemistry
For histological studies, tumors were excised and snap-
frozen in liquid N2, followed by fixation in 4% parafor-
maldehyde/PBS pH 7.4 for 16 h at 4°C. Fixed tumors
were rinsed in PBS and embedded in 5% (w/v) low-melt
agarose (AppliChem, Darmstadt, Germany). Tissue-
sectioning (100 μm) was performed using the Leica
VT1000S Vibratome (Leica, Heerbrugg, Switzerland)
and the labelling procedures were previously described
in detail elsewhere [18].
Fluorescence microscopy
The fluorescence-labelled preparations were examined
using the MZ16 FA Stereo-Fluorescence microscope
(Leica) equipped with the digital DC500 CCD camera
and the Leica IM1000 4.0 software (1300 × 1030 pixel
RGB-color images) as well as the Leica TCS SP2 AOBS
confocal laser microscope equipped with an argon,
helium-neon and UV laser and the LCS 2.16 software
(1024 × 1024 pixel RGB-color images). Digital images
were processed with Photoshop 7.0 (Adobe Systems,
Mountain View, CA) and merged to yield overlay images.
Fluorescence intensity measurements
Fluorescence intensity of the CD31- and MHCII-label-
ling in 100-μm-thick Vibratome sections of control
tumors and infected areas of GLV-1h68-colonized
tumors was measured on digital images (× 50 objective,
× 1 ocular, tissue region 2700 μm by 2150 μm) of speci-
mens stained for CD31 or MHCII immunoreactivity. On
the fluorescence microscope, the background fluores-
cence was set to a barely detectable level by adjusting
the gain of the CCD camera before all the images were
captured with identical settings. RGB-images were con-
verted into 8-bit gray scale images (intensity range 0 -
255) using Photoshop 7.0. The fluorescence intensity of
the CD31-labelling represented the average brightness of
all vessel-related pixels and was measured using Image J
software http://rsbweb.nih.gov/ij. For CD31-labelling the
mean value was calculated for nine images (three images
of three different control and GLV-1h68-infected
tumors) and presented with standard deviation.
The extent of the viral distribution in GLV-1h68-colo-
nized tumors was measured by the GFP fluorescence sig-
nal on digital images (× 10 objective, × 1 ocular, image
size 14 mm by 11.1 mm) of two whole tumor cross-
sections (100 μm) of five or six different tumors. The
whole area of the tumor cross-section was determined by
Hoechst-labelling of cell nuclei. Both, GFP and Hoechst
fluorescence images were converted into 8-bit gray scale
images (intensity range 0 - 255) using Photoshop 7.0.
The background fluorescence of GFP images was set to
the fluorescence intensity of < 20 using Image J software.
A fluorescence intensity of 20 was thus established as the
threshold for distinguishing pixels of the GFP signal from
those of the background. The area of pixels (inch2) on
GFP images (fluorescence intensity > 20) as well as on
Hoechst images (fluorescence intensity > 0) was mea-
sured by Image J and the proportion of infected tissue
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was calculated for two images from each tumors (n = 6).
Mean values + standard deviations are shown.
Measurements of microvessel density and vessel diameter
The vascular density was determined in microscopic
images (× 200 objective, × 1 ocular, tissue region 680
μm by 540 μm) of CD31-labelled tumor sections. On
the fluorescence microscope, for each image the CD31
fluorescence was set to a clearly detectable level by indi-
vidually adjusting the gain of the CCD camera before
the images were captured. All images were decorated
with five horizontal lines at identical positions using
Photoshop 7.0 and all vessels which intersected these
lines were counted to yield the vascular density. The
vascular density was calculated for nine images (three
images of three different control and GLV-1h68-infected
tumors) and presented as mean values with standard
deviations.
The vessel diameter was measured on digital images
(× 200 objective, × 1 ocular) of CD31-labelled 100-
μm-thick tumor cross-sections using Leica IM1000 4.0
software. Images of control and infected tumors
(GLV-1h68-infected area) were obtained with individual
exposure times to get optimal CD31 signals and exclude
signal-dependent variability of vessel diameter. Seven
horizontal lines were drawn across each image and the
diameter of all blood vessels that intersected these lines
was measured (5 images per tumor). Mean values +
standard deviations are shown.
Antibodies, reagents and treatment of animals
Endothelial cells were labelled with monoclonal rat anti-
mouse CD31 antibody (BD PharMingen, San Diego,
CA) or hamster anti-mouse CD31 antibody (Chemicon,
International, Temecula, CA). Pericytes were labelled
with Cy3-conjugated monoclonal mouse anti-mouse
a-smooth muscle actin (SMA) (Sigma Aldrich). Base-
ment membrane was labeled using polyclonal rabbit
anti-mouse collagen IV antibody (Abcam, Cambridge,
UK). Immune cells were labeled using rat anti-mouse
MHCII antibody (B, dendritic cells, monocytes, macro-
phages) and rat-anti mouse CD45 antibody (common
leukocyte antigen) (eBioscience, San Diego, CA).
The Cy3- or Cy5-conjugated secondary antibodies
(donkey) were obtained from Jackson ImmunoResearch
(West Grove, PA).
Phalloidin-TRITC (Sigma Aldrich) was used to label
actin and Hoechst 33342 to label nuclei in tissue
sections.
For the labelling of functional blood vessels in tumors,
mice were anesthetized using 75 mg/kg ketamine and
20 mg/kg xylazine, followed by the injection of 100 μg
of biotinylated-Lycopersicum esculentum lectin (Vector
Laboratories, Burlingame, CA) via the tail vein of the
mice. Two minutes later the chest was opened, and the
vasculature was perfused at a pressure of 120 mmHg
with fixative (4% paraformaldehyde/PBS pH 7.4) from a
cannula inserted into the left ventricle. After fixation,
tumors were removed and prepared for histology.
Tumor cross-sections (100 μm) were labelled with
Cy3-conjugated streptavidin (Sigma Aldrich) to visualize
the lectin-labelled tumor vasculature.
Nonspecific rat-IgG from Jackson ImmunoResearch
was used in extravasation studies and injected intrave-
nously into tumor-bearing mice (11 mg/kg body weight).
After 6 h incubation, the treated tumors were excised
and used for histological analysis. Surface plot profiles
of the IgG extravasation pattern were prepared using
ImageJ software.
For immunosuppression a stock solution of cyclopho-
sphamide monohydrate (42 mg/ml) (Sigma Aldrich) was
prepared in water and sterile filtered. Immediately
before use, the stock solution was diluted 1:1 in 1.8%
NaCl to yield a final concentration of 21 mg/ml. CPA
was administered by intraperitoneal injection twice per
week throughout the entire duration of the study. The
treatment was started 10 days p.i. with an initial dose of
140 mg/kg body weight followed by 100 mg/kg body
weight. The dose and schedule was based on previously
published studies of CPA immunosuppression in mice
and hamsters [19].
Viral replication in vitro
For viral replication assays, tumor cells as well as
endothelial cells were seeded in triplicates into 24-well
plates to reach a confluency of 80% after a culture per-
iod of 12-16 h. Before infection, cell layers were starved
with individual starvation media containing 1% FBS for
24 h and were finally infected with GLV-1h68 at m.o.i.
of 0.01. After 1 h of incubation, the infection medium
was replaced by fresh starvation medium and cells were
cultured for further 6, 24 and 48 h, respectively. At the
indicated time points, cells and supernatants were har-
vested and after three thaw-freeze cycles, serial dilutions
of the lysates were titered by standard plaque assays on
CV-1 cells.
Co-culture experiments
To mimic in vivo conditions, we cultured endothelial
cells on growth factor reduced Matrigel Matrix (BD
Biosciences, Heidelberg, Germany), which is a soluble
basement membrane extract. For co-culture experi-
ments, we coated 24 well plates with 100 μl of Matrigel
for 30 min at 37°C. Endothelial cells (1 × 104 cells/well)
were seeded into 24 well plates and allowed to assemble
into tube-like structures. Three hours later GI-101A-
RFP tumor cells were seeded into these wells and co-
cultures were incubated for 12-15 h. Co-cultures were
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infected with GLV-1h68 at m.o.i. of 0.5 for 1 h, before
the medium was replaced with virus-free medium. The
degree of infection was microscopically determined after
24 h.
Microarray performance and statistical analysis
Total RNA from both infected and uninfected GI-101A
xenografts at days 21 and 42 post VACV infection was
extracted using Trizol reagent (Sigma Aldrich) according
to the manufacturer’s instructions. Total RNA was
amplified into anti-sense RNA (aRNA) as previously
described [20,21] and the quality of both, total RNA and
secondarily amplified RNA was tested with the Agilent
Bioanalyzer 2000 (Agilent Technologies, Palo Alto, CA).
Confidence about array quality was based on the princi-
ple of reference concordance as previously described
[22]. Mouse reference RNA was prepared by homogeni-
zation of the following mouse tissues (lung, heart,
muscle, kidneys and spleen) and RNA was pooled from
4 mice. Pooled reference and test aRNA was isolated
and amplified in identical conditions during the same
amplification/hybridization procedure to avoid possible
inter-experimental biases. Both, reference and test
aRNA was directly labeled using ULS aRNA Fluorescent
labeling Kit (Kreatech, Netherlands) with Cy3 for refer-
ence and Cy5 for test samples.
Whole genome mouse 36 k oligo arrays were printed
in the Infectious Disease and Immunogenetics Section
of the Department of Transfusion Medicine (IDIS), Clin-
ical Center, National Institute of Health, Bethesda using
oligos purchased from Operon (Huntsville, AL). The
Operon Array-Ready Oligo Set (AROS™) V 4.0 contains
35,852 longmer probes representing 25,000 genes and
about 38,000 gene transcripts and also includes 380 con-
trols. The design is based on the Ensembl Mouse Data-
base release 26.33b.1, Mouse Genome Sequencing
Project, NCBI RefSeq, Riken full-length cDNA clone
sequence, and other GenBank sequence. The microarray
is composed of 48 blocks and one spot is printed per
probe per slide. Hybridization was carried out in a water
bath at 42°C for 18-24 hours and the arrays were then
washed and scanned on a Gene Pix 4000 scanner at
variable PMT to obtain optimized signal intensities with
minimum (< 1% spots) intensity saturation.
Resulting data files were uploaded to the mAdb data-
bank http://nciarray.nci.nih.gov and further analyzed
using BRBArrayTools developed by the Biometric
Research Branch, National Cancer Institute [23]http://
linus.nci.nih.gov/BRB-ArrayTools.html and Cluster and
Treeview software [24]. The global gene-expression pro-
filing consisted of 16 experimental samples. Global
expression data were filtered using automated filtering
option of BRBArray software. Therefore, genes involved
in pathways such as “adhesion molecules on lymphocytes,
B lymphocytes cell surface molecule, cytokines and
inflammatory response, monocytes and its surface mole-
cules, neutrophiles and its surface molecules, T cytotoxic
cell surface molecules, T helper cell cytotoxic molecules”
as listed by the Biocarta database were included. Genes
that belonged to at least one of those pathways, that were
present in more than 10 experimental samples (≥ 60%)
and with a fold change of two in at least one sample
passed the filter. Gene ratios were average corrected
across experimental samples. Subsequent cluster analysis
applying uncentered correlation algorithm with genes
involved in selected pathways as listed above allowed
experimental samples to cluster according to their biolo-
gical similarity. Treeview program was used for visualiza-
tion of array data [25].
Statistics
A two-tailed Student’s t test was used for statistical ana-
lysis. P values of < 0.05 were considered statistically
significant.
Results
GLV-1h68 colonization of human breast tumor xenografts
in nude mice leads to specific oncolytic destruction of the
tumor tissue
We have previously reported that viral colonization of
human breast tumor xenografts in nude mice leads to a
remarkable tumor regression over time following a char-
acteristic three-phase growth pattern [16]. After intrave-
neous injection (i.v.) of 5 × 106 pfu (plaque forming
unit) into tumor-bearing mice, GI-101A breast tumors
started to increase in volume during the first three
weeks (Phase I, early phase) reaching a peak volume at
about day 21 (Phase II), and begin then to decline in
size continuously (Phase III, regression phase) (Figure
1a). The volume of colonized tumors about 6 weeks
after virus treatment is only 31% of that of untreated
tumors.
To investigate the localization of viral particles within
colonized tumor xenografts, we analyzed the distribution of
VACV-infected, GFP-expressing cells in histologically pre-
pared whole tumor cross-sections. As shown in Figure 1b
and Additional file 1: Figure 1a, 42 days post infection (p.i.)
a large part (55.25 +/- 7.26%) of the tumor tissue showed
GFP fluorescence indicating extensive viral distribution.
The comparison of GI-101A control tumors with colonized
GI-101A tumors of equivalent age revealed that viral colo-
nization leads to extensive necrotic tissue destruction as dis-
played by the lack of actin cytoskeleton and cell nuclei
labelling (Figure 1b,c). Therefore, much of the tumor mass
that remained and was being measured in GLV-1h68-colo-
nized tumors was actually necrotic debris and calcification.
In contrast, at earlier time points (7 and 21 days p.i.) a
more restricted patch-like distribution pattern of GFP
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fluorescence and necrotic tissue destruction was observed,
revealing the replication- and dissemination-characteristics
of vaccinia virus GLV-1h68 strain (Additional file 1: Figure
1b). The tumor tissue-specific nature of the oncolytic activ-
ity of GLV-1h68 was further supported by the fact that viral
infection was restricted to RFP-expressing tumor cells. Con-
sequently, the ongoing infection leads to a decline of RFP
fluorescence in GI-101A-RFP tumors indicating tumor cell-
specific necrosis (Additional file 1: Figure 1c). Interestingly,
the infected, necrotic tumor tissue at day 42 p.i. was highly
vascularized demonstrated by positive CD31-labelling of the
tumor vasculature in colonized tumor areas (Figure 1d).
This finding supported the specific oncolytic character of
viral-mediated tumor tissue destruction and eliminated the
notion that a loss of blood supply in the infected area could
be the reason for tissue necrosis.
GLV-1h68 does not infect the endothelial cells of the
tumor vasculature
The tumor vasculature is an important part of the
tumor microenvironment which supports tumor growth
by delivery of nutrients, oxygen and immune cells.
Therefore, the destruction of the vascular network in
tumors offers one hypothetical therapeutic strategy for
destruction of the tumor mass [26].
To assess the impact of viral tumor colonization on
the tumor vasculature, we analyzed the CD31-positive
vascular network in tissue sections by confocal micro-
scopy. As shown in Figure 2a, CD31-positive blood
vessels in the infected tumor areas of GI-101A tumors 42
days p.i. are morphologically intact and are not infected
by VACV as indicated by the lack of the colocalization of
CD31-labelling and that of GFP fluorescence. These find-
ings strongly indicate that VACV possesses an inherent
replication-specificity for tumor cells and destruction of
the tumor vasculature is not a prerequisite of the GLV-
1h68-mediated tumor elimination.
To analyze whether blood vessels in GLV-1h68-
infected tumor areas are still functional, we intrave-
nously injected biotinylated-Lycopersicum esculentum
lectin which specifically labels perfused blood vessels.
Indeed, we could demonstrate that the tumor vascula-
ture in the GLV-1h68-colonized areas was perfused and
therefore still connected to the peripheral blood stream
(Figure 2b).
To confirm the cell specificity, we carried out cell cul-
ture infection experiments by comparing viral infectivity
and replication in GI-101A tumor cells and in endothe-
lial cells. We compared three different endothelial cell
lines, two murine cell lines (2H-11, bEnd.3) as well as
Figure 1 Oncolytic destruction of human GI-101A breast tumor
xenografts. GI-101A tumor-bearing mice were intraveneously (i.v.)
injected with 5 × 106 pfu/100 μl PBS GLV-1h68 or PBS as a control.
(a) Tumor growth was monitored weekly by measuring the tumor
volume of six mice in each group. Shown are the mean values +/-
standard deviations. The study was repeated in three independent
experiments. (b, c) Whole tumor cross-sections (100 μm) of GLV-
1h68-infected GI-101A (b) and control tumors (c) 42 days p.i. were
stained with Phalloidin-TRITC (red) to label the actin cytoskeleton
and Hoechst 33342 (blue) to visualize cellular nuclei; GFP
fluorescence (green) indicated viral-infected cells. (d) Serial sections
of whole tumor cross-sections of 42-days-colonized GI-101A tumors
were labelled either with Phalloidin-TRITC (actin) or anti-CD31
antibody (red). In both sections nuclei were stained with Hoechst
(blue) and GLV-1h68-infected cells were indicated by GFP
fluorescence (green). The colonized, necrotic tumor tissue showed a
dense CD31-positive vascular network. All images are representative
examples. Scale bars represent 5 mm (b, c), 2 mm (d).
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one human cell line (HUVEC), to exclude species-speci-
fic endothelial cell differences, which could affect viral
infection. Plaque assays of VACV-infected cell cultures
revealed that highest viral infection and replication
occured in the GI-101A tumor cell line and viral parti-
cles replicated in endothelial cell lines regardless to the
origin significantly lesser (Figure 2c). To more clearly
demonstrate tumor cell specificity of this virus and also
to mimic the tumor infection, we co-cultured GI-101A-
RFP tumor cells and endothelial HUVEC cells on Matri-
gel matrices. The extracellular matrix extract lead to the
formation of tube-like structures composed of endothe-
lial cells surrounded by tumor cells (Figure 2d). The
results demonstrated that only the surrounding tumor
cells were infected by VACV as visualized by GFP fluor-
escence and the internal endothelial cells remained
uninfected (Figure 2d). Similarly, co-culturing of murine
2H11 endothelial cells with GI-101A tumor cells on
Matrigel matrix also showed tumor cell-specific VACV
replication only (data not shown).
Tumor colonization by GLV-1h68 does not stimulate
neo-angiogenesis but upregulates CD31 expression in
endothelial cells and genes involved in leukocytes
recruitment
To address the influence of viral tumor colonization on
the tumor vasculature in GI-101A tumors, we analyzed
first the intensity of CD31-labelling in 42-days GLV-
1h68-infected and control GI-101A tumors. Fluores-
cence intensity of the CD31 signal of blood vessels was
measured in microscopic images in immunohistochemi-
cally stained sections of GI-101A tumors. The results
Figure 2 GLV-1h68 does not infect endothelial cells. (a) Confocal image showing the morphological intact tumor vasculature (arrowheads)
in the GLV-1h68-infected (i.v.) GI-101A tumor tissue 42 days p.i.; the tumor vasculature was labelled with anti-CD31 antibody (red), GLV-1h68-
infection was indicated by GFP (green), and nuclei were stained with Hoechst (blue). (b) Systemic perfusion of the vasculature with lectin
revealed colocalization (arrowhead) of CD31-positive tumor blood vessels (blue) and biotinylated-Lycopersicum esculentum lectin (red). (c) Viral
replication in GI-101A tumor cells, human endothelial (HUVEC) and murine endothelial (2H-11, bEnd.3) cells inoculated with GLV-1h68 at m.o.
i. of 0.01. Infected cells were harvested 6, 24, and 48 h after infection. Shown are viral titers of cell monolayers as p.f.u./cell in triplicate
samples +/- standard deviations determined by plaque assay. (d) Infection of co-cultures of GI-101A-RFP (red) and HUVEC cells (unlabelled)
on Matrigel matrix with GLV-1h68 (green) with m.o.i. 0.5 confirmed the specific infection of tumor cells. The illustration visualized the
formation of tube-like structures composed of endothelial cells surrounded by tumor cells on Matrigel matrices. The asterisk (c) indicate a
significant difference between experimental groups (** P < 0.01; Student’s t test). All images are representative examples. Scale bars represent
75 μm (a) and 300 μm (b).
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revealed that the number of vessel-related pixels in
infected tumor areas increased more than 3-fold in
comparison to non-injected control tumors of same age
(Figure 3a-c).
To determine whether the increase in the CD31
immunofluorescence signal in infected tumors resulted
from an increased vascular density or is due to an
up-regulation of CD31 expression, we analyzed CD31-
labelled cross sections of control and GLV-1h68-colo-
nized tumors in a microscopic study. We selected indi-
vidual exposure times to visualize the CD31-labelled
vasculature in each section independent of the CD31
expression level. Individual exposure times clearly
revealed that there was no quantitative difference in the
vascular density, thus confirmed the viral-infection-
induced upregulation of CD31 in the vasculature of
colonized tumors (Figure 3d).
Since tumor colonization with GLV-1h68 lead to an
up-regulation of CD31, which mediate transendothelial
migration of immune cells to sites of infection, we ana-
lyzed the expression profile of genes involved in leuko-
cytes recruitment in VACV-infected GI-101A tumors
versus uninfected control tumors using a custom-made,
whole genome 36 K mouse array platform. In general,
the analyzed tumor samples showed no characteristic
pro-angiogenic signature, but revealed an significant up-
regulation of genes (e.g. Stat1, Sell, Vcam1, Itgb2, F11r,
Jam3, Cd47, Cd97, Sdc1, Sdc2, Sdc4) involved in leuko-
cyte-endothelial cell interaction and recruitment of
immune cells to sites of infection (Figure 3e).
In summary, VACV-infection of tumor xenografts in
nude mice did not change the vascular density of the
tumor tissue, but altered significantly the expression
profile of tumor-derived endothelial and inflammatory
cells, which may have resulted in an increased recruit-
ment and migration of immune cells to the infected
tumor tissue.
Oncolytic virus infection triggers intratumoral blood
vessel dilatation and increased vascular permeability
The physiological response to infection and injury often
includes vasodilatation, hyperpermeability, and neo-
angiogenesis [27]. To investigate the effect on the tumor
vasculature of long-term viral infection in the GI-101A
breast tumor model, we measured the diameter of blood
vessels in 42-days infected and uninfected control GI-
101A tumors. The results, shown in Figure 4a, indicated
that VACV infection (42 days p.i.) of the tumor tissue
leads to a significant increase in vessel size (mean dia-
meter 24.17 +/- 9.07 μm) in infected tumor areas com-
pared to control tumors (10.09 +/- 4.01 μm).
Pericytes are another key component in vascular
development, stabilization, maturation, and remodeling
and are intimately associated with endothelial cells [28].
To analyze pericyte coverage in 42-days infected and
uninfected control tumors, we compared a-SMA label-
ling in tumor cross-sections. Control tumors showed a
large number of pericytes loosley attached to the tumor
vasculature (Figure 4b). In contrast, however, VACV-
infection of GI-101A tumors leads to regression and/or
destruction of pericytes in the VACV-infected tumor tis-
sue (Figure 4b).
Since the loss of pericytes may influence vessel perme-
ability and tumor perfusion, we were interested to see
whether the extravasation pattern of intraveneously
injected Immunoglobulins (IgGs) differ in GLV-1h68-
treated and untreated GI-101A tumors. Indeed, viral
infection of the tumor tissue resulted in elevated extra-
vasation of unspecific rat IgGs in colonized tumor areas
(Figure 4c). Further, the comparison with control
tumors revealed a heterogeneous intratumoral IgG
extravasation pattern in control tumors (Figure 4c) and
a locally restricted IgG extravasation pattern in GLV-
1h68 infected tumor areas (Figure 4c), which indicated
that the permeability of tumor vessels in infected tumor
areas was strongly increased. Together, these results
suggested that tumor colonization with GLV-1h68 acti-
vated the tumor endothelium which leads to increased
tumor perfusion and leakage of blood-borne particles.
Viral infection induces massive leukocytes recruitment via
the activated tumor vasculature
The activated endothelium is characterized by vascular
hyperpermeability and increased expression of adhesion
molecules, which facilitate perivascular inflammatory cell
infiltration [29]. We demonstrated above that tumor colo-
nization with the oncolytic GLV-1h68 strain lead to
increased hyperpermeability as well as to the up-regulation
of the adhesion molecule CD31, which is directly involved
in the transmigration of leukocytes via the endothelial bar-
rier. Therefore, we analyzed the extent of tumoral leuko-
cytes recruitment in GLV-1h68-infected and control mice.
Indeed, 42-days colonized GI-101A tumors revealed an
intense intratumoral recruitment of MHCII-positive cells
(monocytes/macrophages, dendritic cells and B cells) to
tumor xenografts compared to uninfected control GI-
101A tumors of same age (Figure 5a,b, Additional file 2:
Figure 2a,b). Interestingly, we found that the extensive
viral load in the tumor tissue seem to be the trigger for
massive leukocytes recruitment. In comparison less
infected GLV-1h68-infected tumors at earlier time points
(21 days p.i.) showed only slight recruitment of leukocytes
(Additional file 2: Figure 2c,d). In addition, we could also
show specific recruitment of CD45-positive leukocytes
(common leukocyte antigen) around viral patches indicat-
ing an immunological response against GLV-1h68-
infected cells (Figure 5c). Detailed microscopic analysis
showed that a large number of CD45-positive as well as
Weibel et al. BMC Cancer 2011, 11:68
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Figure 3 Viral tumor infection activates the tumor vasculature. Athymic nude mice bearing human GI-101A tumors were injected with 5 ×
106 pfu of GLV-1h68 and tumors were harvested 42 days p.i. (a-c) GLV-1h68-colonized GI-101A tumors showed increased CD31 fluorescence
intensity compared to GI-101A control tumors. The tumor vasculature was labelled with anti-CD31 antibody (red) and the fluorescence signals in
9 images (x50 magnification) were measured using ImageJ. Shown are the mean values +/- standard deviations. (e) GLV-1h68-infected and
control GI-101A tumors showed the same level of vascularization. Vascular density was measured in CD31-labelled tumor cross-sections (nine per
group). Shown are the mean values +/- standard deviations. (d) Gene expression profile of both, VACV infected and uninfected GI-101A
xenografts 21 and 42 days p.i. Genes were selected based on pathway analysis as described in material and methods and clustered using
uncentered correlation algorithm. Genes that passed the filtering criteria (at least 2fold change in one experiment and 60% presence call across
the experimental set) are displayed. The asterisk (a) indicate a significant difference between experimental groups (*** P < 0.001; Student’s t test).
All images are representative examples. Scale bars represent 500 μm (a, b).
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MHCII-positive leukocytes were associated with the tumor
vasculature, which may represent sites of actively ongoing
leukocytes recruitment via the activated tumor vasculature
(Figure 5d,e).
Viral-mediated inflammation creates an “immunovascular
memory” in colonized GI-101A tumors
It is already described for atherosclerosis that infectious
agents may lead to enhanced accumulation of monocytes/
macrophages at the endothelium which are surrounded by
an increased deposition of extracellular matrix components
(e.g. collagen). This vessel-associated accumulation of
immune cells serve as an “immunovascular memory” which
lead to an ever-growing immunological response by reitera-
tive immune cell recruitment [30]. To test whether similar
morphological alterations of the tumor vasculature may
occur in response to tumor colonization with GLV-1h68,
we analyzed the interaction of MHCII-positive leukocytes
Figure 4 GLV-1h68 colonization of GI-101A tumors leads to blood vessel dilatation, destruction of pericytes, and increased vessel
permeability. Athymic nude mice bearing human GI-101A tumors were retro-orbitally (r.o.) injected with 5 × 106 pfu of GLV-1h68 and tumors
were harvested 42 days p.i. (a) GLV-1h68-colonized GI-101A tumors showed increased vessel size (mean diameter 24.17 +/- 9.07 μm) compared
to GI-101A control tumors (10.09 +/- 4.01 μm). The tumor vasculature was labelled with anti-CD31 antibody (red) and the diameter of all blood
vessels (12-18 vessels/image) in 5 images (× 200 magnification) was measured using Leica IM1000 4.0 software. Shown are the mean values +/-
standard deviations. (b) Confocal images showed destruction of pericytes in GLV-1h68-infected GI-101A tumors. Pericytes were labelled using
Cy3-conjugated anti-SMA antibody (red), tumor vasculature was labelled with anti-CD31 antibody (blue), and viral infection was indicated by GFP
fluorescence (green). (c, d) Extravasation of unspecific rat IgGs in 42-days-colonized (c) and control GI-101A tumors (d); mice were injected with
11 mg/kg rat IgGs 6 h before the tumors were fixed, histologically prepared and labelled with Cy3-conjugated anti-rat antibody to visualize
extravasated IgGs (red). The tumor vasculature was labelled with anti-CD31 antibody (blue), GLV-1h68-infection was indicated by GFP (green),
and nuclei were stained with Hoechst (orange). Surface plot profiles (ImageJ) of the fluorescence intensity of rat IgGs measured in whole tumor
cross-sections demonstrate the enhanced extravasation of IgGs in GLV-1h68-colonized tumors. The asterisk (a) indicate a significant difference
between experimental groups (*** P < 0.001; Student’s t test). All images are representative examples. Scale bars represent 500 μm (a), 300 μm
(b), 1 mm (c, d).
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with the tumor vasculature in detail. Indeed, we could
identify a close association of MHCII+/CD31+ cells
(vascular leukocytes) with the CD31-positive tumor
vasculature, which is restricted to massively infected,
late-stage (42 days p.i., Phase III) GLV-1h68-colonized
GI-101A tumors (Figure 6a) and not detectable in con-
trol tumors (Figure 6b). Additional detailed confocal
microscopic analysis revealed that the MHCII+/CD31+
cells invaded the endothelial intima and accumulated
around tumor vessels (Figure 6c).
Figure 5 Induced leukocyte recruitment via the activated tumor vasculature in GLV-1h68 infected tumors. GI-101A tumor-bearing mice
were i.v. injected with 5 × 106 pfu of GLV-1h68 and tumors were harvested 42 days p.i. (a, b) Whole tumor cross-sections of GLV-1h68-infected
tumors (a) and control GI-101A tumors (b) were labelled with anti-MHCII antibody to visualize the recruitment of MHCII-positive leukocytes. (c)
Confocal image of GLV-1h68-colonized tumors revealed accumulation of CD45-positive leukocytes around viral patches. (d, e) Confocal images
showed intense interaction of CD45-positive (d) and MHCII-positive leukocytes (e) with the CD31-positive tumor vasculature. Immune cells were
labelled with anti-MHCII antibody (red; a, b, e) or anti-CD45 antibody (red; c, d); nuclei were visualized using Hoechst (blue in a, b; orange in c, d,
e), tumor vasculature was labelled with anti-CD31 antibody (blue) and viral infection was indicated by GFP fluorescence (green). All images are
representative examples. Scale bars represent 1 mm (a, b), 300 μm (c-e).
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Furthermore, the analysis of the type IV collagen-
containing basal membranes of the tumor vasculature in
42-days colonized GI-101A tumors and uninfected con-
trol tumors, showed thickened collagen matrices around
vessels in GLV-1h68-colonized tumors only (Figure 6d).
Lastly, we could identify a space between CD31-positive
endothelial cells and the thickened basal membrane only
in viral-infected GI-101A tumors (Figure 6d,e).
These results strongly suggests that oncolytic treat-
ment of human xenografts lead to the accumulation of
MHCII-positive cells in late infection stages located
between the endothelial lining and the subjacent, thick-
ened basal lamina. This virus-induced formation of local
atherosclerotic tumor vessels may serve as a potential
“immunovascular memory”.
The role of leukocytes in the GLV-1h68-mediated tumor
elimination
We have seen an enormous recruitment of MHCII-
positive leukocytes in late infection stages (regression
phase III) of GLV-1h68-infected GI-101A tumors, there-
fore, we set out to analyze the role of the leukocytes in
the viral-mediated tumor elimination process.
To determine the contribution of recruited immune
cells to rejection of virally infected GI-101A tumors, we
treated infected and uninfected tumor-bearing nude mice
with the broad-spectrum immunosuppressive agent CPA
[19,31]. We started with CPA-treatment 10 days p.i. to
establish substantial viral burden in all experimental
groups, however, temporally still before massive infiltra-
tion of immune cells occurred (data not shown). The eva-
luation of immunosuppression by CPA in nude mouse
models revealed that the recruitment of MHCII-positive
cells in CPA-treated, VACV-infected GI-101A tumor-
bearing mice significantly decreased in comparison to
untreated, VACV-infected GI-101A tumor-bearing mice
(Figure 7a). Furthermore, the histological examination of
spleen sections showed also reduced MHCII-positive cell
densities in the monocyte/macrophage-containing red
pulp, whereas the B-cell-containing white pulp was not
Figure 6 Association of MHCII-positive leukocytes with the tumor vasculature. GI-101A tumor-bearing mice were i.v. injected with 5 × 106
pfu GLV-1h68 and tumors were harvested 42 days p.i., prepared immunohistologically and examined using confocal microscopy. (a, b)
Association of MHCII-positive leukocytes cell cluster with the CD31-positive tumor vasculature (arrowhead) in GLV-1h68-infected tumors (a);
isolated MHCII-positive cells in control tumors (b). (c) MHCII+/CD31+ cell invasion (arrowhead) of the endothelial intima and accumulation around
tumor vessels. (d, e) The type IV collagen IV-containing basal membrane (red) of the tumor vasculature was thickened and loosley attached to
endothelial cells (arrowhead) in GLV-1h68-infected tumors (d) compared to control tumors (e). MHCII-positive leukocytes were labelled with anti-
MHCII antibody (red; a-c); tumor vasculature was marked with anti-CD31 antibody (blue), GFP fluorescence indicate viral-infected cells, and nuclei
were stained with Hoechst (green in c; orange in d, e). All images are representative examples. Scale bars represent 300 μm (a, b), 75 μm (c-e).
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affected (data not shown). To determine whether the
immune system (mainly MHCII-positive monocytic cells)
was instrumental in or detrimental to oncolytic VACV
efficacy, we evaluated the tumor growth pattern of unin-
fected and VACV-infected tumor-bearing animals either
treated or untreated with CPA. In general, CPA treat-
ment of uninfected GI-101A tumor-bearing mice did
not per se significantly change the tumor growth pattern
(Figure 7b). The CPA-treated, VACV-infected group
showed no significant difference in the tumor growth
characteristics compared to the untreated, VACV-
infected group. However, the study also revealed that
tumors of CPA-treated, VACV-infected animals showed
earlier regression suggesting a more effective viral repli-
cation which may be due to the elimination of an anti-
viral immune responses.
To investigate the effect of immunosuppression on
viral replication and distribution within the tumor tis-
sue, which determines the degree of viral-mediated
tumor oncolysis, we measured the virus content in
tumors using GFP-imaging and the content of viable
tumor cells using Hoechst-labelling. The histological
analysis of the viral distribution (equivalent to GFP) in
CPA-treated and untreated animals revealed that the
extent of the GFP-positive area in immunosuppressed
tumors was significantly increased compared to
untreated tumors (Figure 7c-e). Therefore, necrotic
destruction of the tumor tissue in CPA-treated, VACV-
infected animals is more pronounced than in untreated,
infected animals as shown by decreased Hoechst-
labelling of viable tumor cells.
To analyze the contribution of T-, B-, and NK-cells to
the VACV-mediated tumor regression process, we ana-
lyzed human GI-101A tumor growth upon VACV infec-
tion in athymic nude Foxn1nu (T-cell-deficient),
B6.12956-Rag2tm1Fwa N12 (T-, B-cell-deficient), and Tac:
NIHS-LystbgFoxn1nuBtkxld (T-, B-, NK-cell-deficient)
mouse strains. The tumor growth curves showed similar
tumor growth and regression characteristics in all three
mouse models (Figure 7f-h). Therefore, these immune
cells did not contribute to VACV-activated anti-tumoral
immune response and are not required for VACV-
mediated tumor regression.
In summary, the results suggest that neither the
MHCII-positive immune cells nor the T-, B-, or NK-
cells are major contributors to VACV-mediated GI-
101A tumor regression.
Discussion
The mechanisms involved in tumor regression during
oncolytic therapy are still a matter of heated debate.
They may naturally vary among different tumor models
and/or be dependent on different oncolytic virus strains
used. Predominantly, oncolytic viruses are effective
therapeutic agents due to their ability to efficiently infect
and destroy cancer cells. In addition, replicating viruses
may interfere with components of the tumor microen-
vironment such as the tumor vasculature and the
immune system of the host. Therefore, oncolytic tumor
destruction may be a multi-step process, in which the
different components work with or against each other.
In this study, we show that the oncolytic VACV GLV-
1h68 drastically interfered with host components such
as the tumor vasculature and induced also a massive
innate immune response. But the predominant mechan-
ism which leads to regression of tumors, in this model
at late stage of tumor regression, was found to be direct
viral-infection-mediated tumor cell destruction.
In contrast, Breitbach et al [32] showed that a signifi-
cant portion of the tumor killing activity of vesicular
stomatitis virus and VACV in the murine CT-26 colon
cancer model is caused by indirect killing of uninfected
tumor cells. In this tumor model the authors suggest
that massive neutrophil activation followed by vascular
damage and apoptosis of uninfected tumor cells one day
after infection are the main cause of tumor cell destruc-
tion. However, the tumor killing may be caused by the
high viral titer (1 × 109 pfu) used in the study to infect
tumor-bearing animals. Further, the large amount of
activated neutrophils may occlude the abnormal tortu-
ous tumor vessels and the oxitative burst may directly
destroy endothelial cells leading to vascular shutdown
followed by apoptosis of surrounding tumor cells. In
contrast we showed, that tissue necrosis exactly coloca-
lizes with GFP-expressing VACV-infected tumor cells in
human breast tumor xenografts. Interestingly, the
infected, necrotic tumor areas remain highly vascular-
ized in late infection stages (42 dpi). Therefore, neither
vascular shutdown nor other indirect killing activities
seem to occur and tumor destruction parallels with the
site of viral replication and spreading.
Destruction of the tumor vasculature seems to be, in
general, a promising strategy to induce tumor shrinkage
by deprivation of nutrients and oxygen. In this regard, the
oncolytic viruses itself may target, infect and destroy the
tumor vasculature. For example, Kirn et al. [14] showed
that an oncolytic vaccinia virus mutant strain with B18R
deletion infects and destroys tumor-associated vascular
endothelial cells. In contrast, we did not find any infected
endothelial cells in tumors nor did the GLV-1h68 strain
show general replication in murine or in human endothe-
lial cell lines. On the other hand, combination of oncolytic
viruses with anti-angiogenic therapy also appeared to
enhance virotherapy, possibly due to the stabilization of
the tumor vasculature or reducing the neovascular
responses associated with viral replication [33-35]. Numer-
ous therapy approaches are described using oncolytic
viruses in combination with anti-angiogenic molecules to
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Figure 7 MHCII-positive immune cells, T-, B-, and NK cells did not significantly contribute to VACV-mediated tumor regression. GI-101A
tumor-bearing mice were intraveneously (i.v.) injected with either 5 × 106 pfu/100 μl GLV-1h68 (a-e) or 1 × 106 pfu/100 μl GLV-1h68 (f-h) or PBS
as a control. Immunosuppression was reached using 100/140 mg/kg cyclophosphamide monohydrate. (a) Fluorescence intensity measurement
of recruited MHCII+ leukocytes in GLV-1h68 infected GI-101A tumors treated or untreated with CPA. The fluorescence signal was measured in
4 images of each tumor (n = 5). Shown are the mean values +/- standard deviations. (b) Tumor growth was monitored weekly by measuring
the tumor volume of five mice in each group. Shown are the mean values +/- standard deviations. The study was repeated in an independent
experiment. CPA treatment was started 10 days p.i. (arrow). (c-e) Distribution of GLV-1h68 within the tumor tissue 42 days p.i. was visualized by
GFP in whole tumor cross-sections of 5 different tumors; the corresponding 8-bit grey-scale images of GFP and nuclei were used for calculation
of the extent (%) of viral infection in tumor cross-sections using ImageJ software. Shown are the mean values +/- standard deviations. (d, e)
Representative images of CPA-treated GLV-1h68-infected tumor (d) compared to untreated GLV-1h68-infected tumor (e) revealed a higher
degree of oncolytic tissue destruction. (f-h) Tumor growth in athymic nude Foxn1nu (f), B6.12956-Rag2tm1Fwa N12 (g), and Tac:NIHS-
LystbgFoxn1nuBtkxld (h) mice was monitored weekly by measuring the tumor volume of four to five mice in each group. In all models mice were
intraveneously (i.v.) injected with 1 × 106 pfu/100 μl GLV-1h68 at day 39 post tumor cell implantation. Shown are the mean values + standard
deviations. The asterisk (a, c) indicate a significant difference between experimental groups (* P < 0.05, *** P < 0.001; Student’s t test). Scale bars
represent 5 mm.
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potentiate tumor destruction [11,12,34,36]. Beside the
widely discussed starvation effects exhibited by angiogen-
esis-inhibitors, the destruction or normalization of the
tumor vasculature may also have effect on the host
immune response, due to a reduced infiltration of innate
immune cells in the infected tumor tissue, which in turn
affects virus survival.
In general, the vascular endothelium regulates innate
and adaptive immune responses by controlling the
extravasation of leukocytes from the blood into the
inflamed tissue [27,29]. During inflammation, these
patroling leukocytes extravasate into the tissue via a
sequential process that is initiated by their adhesion to
endothelial cells, which in turn leads to endothelial cell
activation [29]. The activated endothelium is character-
ized by vascular hyperpermeability and increased tissue
edema, which in turn facilitates perivascular inflamma-
tory cell infiltration. The tumor vasculature in GLV-
1h68-infected areas strongly resembles the activated
endothelium in inflamed tissue, which is supported by
the increased expression of CD31, the up-regulation of
genes involved in leukocytes recruitment as well as the
observed vasodilatation and hyperpermeability. However,
the inflammatory response of the endothelium remains
mainly localized in and directly around viral patches
within the tumor tissue. At least, the encapsulation of
viral patches by CD45- as well as MHCII-positive leuko-
cytes indicated that the viral-induced immune response
is mainly restricted to the invader and seems not to be a
general anti-tumoral response in the late tumor regres-
sion phase.
Detailed confocal analysis of the tumor vasculature in
late-stage infected tumors revealed a cell population, not
yet described in the context of oncolytic tumor therapy,
which coexpresses endothelial (CD31) and dendritic cell
markers (CD45, MHCII) [37]. Recently, Conejo-Garcia
et al. [37] described this novel leukocyte subset within
ovarian carcinomas and attributed this cells to have the
capacity to generate functional blood vessels in tumors.
During oncolytic tumor therapy, this cell population
may stabilze or partly restore the tumor vasculature
within the infected, necrotic tumor areas, which repre-
sent truly unfavourable conditions for cell survival.
The observed phenomenon of vasodilatation as well as
the increased permeability could also be enhanced by
necrosis of the vessel-surrounding area, including
destruction of pericytes, which reduces mechanical stress
on the tumor vasculature leading to decompression of
tumor vessels. Recently, Padera et al [38] showed, that
tumor-specific cytotoxic therapy results in more efficient
drug delivery by decompressing collapsed vessels. There-
fore, we suppose that oncolytic VACV could be used as a
“natural enhancer” of chemotherapy by improving the
intratumoral dissemination of chemotherapeutics.
The relative importance of direct oncolysis versus
immune-mediated tumor regression remains in most of
the animal models uncertain. In general, xenografts are
considered as chronically inflamed and do not by them-
selves provide sufficient signals to induce an acute
inflammation leading to immune-mediated rejection of
the tumor [39]. The generation of an effective anti-
tumoral immune response depends on danger signals
within the tumor, and infectious agents inherently offer
these sufficient signals [40,41]. Therefore, viral infection
of the tumor tissue may generate the essential trigger to
alter the immune milieu of the tumor microenviron-
ment. To elucidate whether the initiated immune
response is directed against the viral invader or against
the tumor tissue, we used the previously reported
immunosuppressive agent CPA [19,31] to deplete virus-
induced intratumoral immune cell recruitment. The
tumor growth curve analysis showed no significant dif-
ference in the tumor growth characteristics between
CPA-treated and CPA-untreated VACV-infected GI-
101A tumors. However, we propose here that in general,
factors such as viral distribution/degree of oncolysis or
extent of tissue destruction/necrosis and correlation e.g.
to the recruitment of immune cells offer much more
information about therapy success than the tumor
volume alone, because the tumor volume that was mea-
sured could be either necrotic debris or host cells of the
tumor microenvironment instead of cancer cells. Our
study showed that the extent of viral distribution/
necrotic tissue destruction increased in CPA-treated,
VACV-infected tumors and correlated with reduced
intratumoral MHCII-positive immune cell infiltration
compared to untreated, VACV-infected tumors.
Although there is no significant change in the tumor
growth characteristic upon immunosuppression, the sig-
nificant higher extent of viral distribution/necrosis in
these animals indicates that MHCII-positive immune
cells impede viral-mediated tissue destruction. According
to data shown here, immunosuppression increases onco-
lytic effects of a herpes simplex virus-derived OV [42] as
well as an oncolytic adenovirus [19] via enhancing intra-
tumoral viral spread. Further, Fulci et al [42] showed via
clodronate liposome-dependent depletion of phagocytic
cells, that mainly cells of the monocytic origin are
responsible for clearance of intratumoral viral particles.
The immunolgical response against GLV-1h68, how-
ever, is not effective enough to eliminate the virus from
the tumor tissue. This may be due to the wealth of
immune evasion mechanisms presented by vaccinia
virus [43]. Furthermore, the recruited immune cells may
not as cytotoxic as usual due to the local immunosup-
pressing tumor microenvironment and can only slow
down viral spread but not eliminate the viral infection
focus. Alternatively, these recruited immune cells, which
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encapsulate viral patches, form an anatomical barrier,
which may not be overcome by the virus due to their
lesser susceptibility to VACV infection.
Previously, we have shown by transcriptional profiling
of different tumor models that oncolytic GLV-1h68
infection does induce strong pro-inflammatory signa-
tures [44,45]. Recently, Wang et al. [39] postulated that
viral infection of the tumor tissue generates the neces-
sary trigger that activates an acute immune response
against the tumor tissue. However, the here described
data revealed, that the immunological response in GLV-
1h68-mediated GI-101A tumor destruction represents
indeed an acute inflammation, but this response is only
directed against the “pathogen” and not against the
tumor tissue. We could show here that neither MHCII-
positive immune cells nor T-, B-, or NK cells contribute
significantly to VACV-mediated tumor regression. Col-
lectively, these data support the primarily oncolytic
character of VACV-mediated tumor destruction and
demonstrate that the activation of a direct anti-tumoral
immune response was not critical for tumor regression
in this tumor model.
Conclusions
In summary, the here presented results described the
mechanism leading to oncolytic tumor therapy and
highlighted the ongoing acute inflammation in the
infected tumor tissue. The study revealed, supported by
use of immunosuppressed animals, that the activated
host response is directed against the invading virus and
not against the tumor tissue. Therefore, we assume that
targeted, local immunosuppression of tumors during
oncolytic therapy should enhance VACV-mediated
tumor tissue destruction and improve therapeutic out-
come. Furthermore, the VACV-induced local inflamma-
tion within the tumor presents an ideal condition for
therapeutic approaches, which combine oncolytic viruses
with systemically injected chemotherapeutics due to the
VACV-mediated enhanced tumor perfusion.
Additional material
Additional file 1: Specific oncolytic destruction of human GI-101A
breast tumor xenografts. GI-101A tumor-bearing mice were
intraveneously (i.v.) injected with 5 × 106 pfu GLV-1h68. (a) Distribution
of GLV-1h68 within the tumor tissue 42 days p.i. was visualized by GFP in
whole tumor cross-sections of 6 different tumors; the corresponding 8-
bit grey-scale images of GFP and nuclei were used for calculation of the
extent (%) of viral infection in tumor cross-sections using ImageJ
software. 55.25 +/- 7.26% of tumor cross-sections were colonized with
GLV-1h68. (b) Whole tumor cross-sections (100 μm) of GLV-1h68-infected
GI-101A tumors 7 and 21 days p.i. were stained with Phalloidin-TRITC
(red) to label the actin cytoskeleton and Hoechst 33342 (blue) to
visualize cellular nuclei; GFP fluorescence (green) indicated viral-infected
cells. GLV-1h68-infection was restricted to small patches within the tumor
tissue at early infection time points. (c) Infection of GI-101A-RFP tumors
with GLV-1h68 (green) revealed specific infection of RFP-expressing GI-
101A tumor cells (red) 42 days p.i. The comparison of the RFP
fluorescence intensity in 21- and 42-days-colonized tumors showed a
decrease in the RFP signal 42 days p.i. demonstrating specific oncolytic
tumor cell destruction. All images are representative examples. Scale bars
represent 5 mm (a-c).
Additional file 2: Recruitment of leukocytes - massive intratumoral
recruitment in 42-days-infected tumors and weak recruitment at
earlier time points. (a, b) 42-days-infected (left image in a, b) and
control GI-101A tumors (right image in a, b) were labelled with anti-
MHCII antibody (red) to visualize tumoral leukocyte recruitment. Confocal
images showed peritumoral (a) and increased intratumoral
(b) recruitment of MHCII-positive cells in GLV-1h68-infected tumors
compared to control tumors; nuclei were visualized using Hoechst (blue);
GLV-1h68-infected tumors showed GFP fluorescence (green). (c, d) 21-
days-infected GI-101A tumors were labelled with anti-MHCII antibody
(c) or anti-CD45 antibody (d). Early-infection stages of GI-101A tumors
showed only mild, peritumoral recruitment of leukocytes. All images are
representative examples. Scale bars represent 300 μm (a, b), (c) 2 mm.
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